Painbloc24
Capsaicin 0.25%
Vizuri Health Sciences Llc
Human Otc Drug
NDC 71226-001Painbloc24 also known as Capsaicin 0.25% is a human otc drug labeled by 'Vizuri Health Sciences Llc'. National Drug Code (NDC) number for Painbloc24 is 71226-001. This drug is available in dosage form of Solution. The names of the active, medicinal ingredients in Painbloc24 drug includes Capsaicin - 2.5 mg/mL . The currest status of Painbloc24 drug is Active.
Drug Information:
| Drug NDC: | 71226-001 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Painbloc24 |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Capsaicin 0.25% |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Vizuri Health Sciences Llc |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Solution |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | CAPSAICIN - 2.5 mg/mL
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | TOPICAL
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | OTC MONOGRAPH NOT FINAL |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 21 Mar, 2017 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 21 Dec, 2025 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Application Number: | part348 |
| This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null. |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | Vizuri Health Sciences LLC
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| RxCUI: | 1874747
|
| The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| UNII: | S07O44R1ZM
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 71226-001-01 | 1 BOTTLE, WITH APPLICATOR in 1 CARTON (71226-001-01) / 30 mL in 1 BOTTLE, WITH APPLICATOR | 21 Mar, 2017 | N/A | No |
| 71226-001-02 | 1 BOTTLE, WITH APPLICATOR in 1 CARTON (71226-001-02) / 14 mL in 1 BOTTLE, WITH APPLICATOR | 01 Aug, 2017 | N/A | No |
| 71226-001-03 | 1 BOTTLE, WITH APPLICATOR in 1 CARTON (71226-001-03) / 45 mL in 1 BOTTLE, WITH APPLICATOR | 01 Aug, 2017 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Purpose:
Purpose topical analgesic
Product Elements:
Painbloc24 capsaicin 0.25% alcohol diethylene glycol monoethyl ether hyaluronate sodium polysorbate 80 propylene glycol water capsaicin capsaicin
Indications and Usage:
Uses for the temporary relief of minor aches and pains of muscles and joints associated with: arthritis simple backache muscle strains bruises sprains
Warnings:
Warnings for external use only when using this product use only as directed do not bandage tightly or cover treated area do not use with heating pad avoid contact with eyes and mucous membranes do not apply to wounds, damaged, broken or irritated skin do not expose the area treated with product to heat or direct sunlight if using before exercise, showering or swimming, apply, wait 30 minutes, then wash off before participating a temporary burning sensation and/or redness may occur upon application. this is normal and generally stops after a few days of use stop use and ask a doctor if severe burning sensation occurs you experience difficulty breathing or swallowing condition worsens redness persists, spreads or becomes tender irritation develops symptoms last more than 7 days or clear up and occur again within a few days if pregnant or breast-feeding, ask a healthcare professional before use. keep out of reach of children. if swallowed, get medical help or contact a poison control cent
Read more...er right away.
When Using:
When using this product use only as directed do not bandage tightly or cover treated area do not use with heating pad avoid contact with eyes and mucous membranes do not apply to wounds, damaged, broken or irritated skin do not expose the area treated with product to heat or direct sunlight if using before exercise, showering or swimming, apply, wait 30 minutes, then wash off before participating a temporary burning sensation and/or redness may occur upon application. this is normal and generally stops after a few days of use
Dosage and Administration:
Directions adults over 18 years: apply to affected area using roller ball until visibly moist allow to dry repeat application, as needed, every 12 to 24 hours do not use more than a twice a day wash hands with soap and water after each application may take several days to reach full effect
Stop Use:
Stop use and ask a doctor if severe burning sensation occurs you experience difficulty breathing or swallowing condition worsens redness persists, spreads or becomes tender irritation develops symptoms last more than 7 days or clear up and occur again within a few days
Package Label Principal Display Panel:
Principal display panel - 14 ml bottle carton vizuri pain bloc ® 24 24 hours of arthritis pain relief* capsaicin capsaicin 0.25% topical analgesic max dose without a prescription odor free â arthritis foundation ® let's get a grip on arthritis. 0.5 fl oz (14 ml) ndc:71226-001-02 principal display panel - 14 ml bottle carton
Further Questions:
Questions call 855-438-3944